{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:44:41Z","timestamp":1792097081849,"version":"4.4.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jaccas.2026.109754","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:25:27Z","timestamp":1787225127000},"page":"109754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Novel Use of Mavacamten in RAF1-Associated Noonan Syndrome With Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"31","author":[{"given":"Lubna","family":"Ziauddin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Spears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markey","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hendren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8157-8899","authenticated-orcid":false,"given":"Sheila M.","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Grodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Tapaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccas.2026.109754_bib1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaccas.2026.109754_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000276766","article-title":"Noonan syndrome: clinical aspects and molecular pathogenesis","volume":"1","author":"Tartaglia","year":"2010","journal-title":"Mol Syndromol"},{"issue":"9863","key":"10.1016\/j.jaccas.2026.109754_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaccas.2026.109754_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.010687","article-title":"Targeted therapies in pediatric and adult patients with hypertrophic heart disease: from molecular pathophysiology to personalized medicine","volume":"16","author":"Monda","year":"2023","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jaccas.2026.109754_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacbts.2024.10.002","article-title":"Impact of MEK inhibition on childhood RASopathy-Associated Hypertrophic Carhiomyopathy","volume":"10","author":"Wolf","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"13","key":"10.1016\/j.jaccas.2026.109754_bib6","article-title":"Treatment of RAF1-related obstructive hypertrophic cardiomyopathy by MEK inhibition using trametinib","volume":"29","author":"Kiamanesh","year":"2024","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.jaccas.2026.109754_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCULATIONAHA.118.037227","article-title":"Inducible pluripotent stem cell-derived cardiomyocytes reveal aberrant extracellular regulated kinase 5 and mitogen-activated protein kinase kinase 1\/2 signaling concomitantly promote hypertrophic cardiomyopathy in RAF1-associated Noonan syndrome","volume":"140","author":"Jaffr\u00e9","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccas.2026.109754_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.125.074155","article-title":"Targeting interleukin-8-mediated cellular crosstalk reverses hypertrophic cardiomyopathy and cardiac fibrosis in Noonan syndrome","author":"Fell","year":"2026","journal-title":"Circulation"},{"issue":"Supplement_1","key":"10.1016\/j.jaccas.2026.109754_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag115.083","article-title":"PO88 Mavacamten in Noonan syndrome: clinical benefits mediated by an off-target mechanism","volume":"33","author":"Marchionni","year":"2026","journal-title":"Eur J Prev Cardiol"},{"issue":"19","key":"10.1016\/j.jaccas.2026.109754_bib10","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.jaccas.2026.109754_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.041565","article-title":"Mavacamten in symptomatic patients resistant to previous advanced therapy for obstructive hypertrophic cardiomyopathy","volume":"14","author":"Massera","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jaccas.2026.109754_bib12","article-title":"Comprehensive improvement in cardiac function following myosin inhibition after the ineffectiveness of myectomy and alcohol septal ablation: a case report","volume":"9","author":"Aleksandrov","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"10.1016\/j.jaccas.2026.109754_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.xjon.2025.07.007","article-title":"Chemical myectomy with mavacamten in patients with obstructive hypertrophic cardiomyopathy with prior septal reduction therapy: a single-center experience","volume":"27","author":"Hundal","year":"2025","journal-title":"JTCVS Open"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926029153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084926029153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:53Z","timestamp":1792093793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084926029153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":13,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666084926029153"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109754","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Use of Mavacamten in RAF1-Associated Noonan Syndrome With Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.109754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"109754"}}